Table 2 Secondary outcome variables of surviving infants for the ATP population (placebo group n = 28, ESTRA‐PRO group n = 21; two sided testing).

Outcome variable	Placebo	ESTRA‐PRO	p Value
Cumulative dose of surfactant (mg/kg)	163 (0–402)	153 (64–330)	0.84
Mechanical ventilation (days)	20 (2–72)	20 (2–51)	0.32
Time at first extubation (days)	9 (0–45)	6 (0–32)	0.41
Length of hospital stay (days)	123 (57–225)	106 (76–156)	0.01
Body weight at discharge (g)	3290 (2000–4230)	2830 (2020–5150)	0.03
Pneumothorax	2 (7)	2 (10)	1.00
Pulmonary interstitial emphysema	5 (18)	4 (19)	1.00
Treatment with dexamethasone	2 (7)	6 (29)	0.05
Persistent ductus arteriosus	4 (14)	6 (29)	0.29
Intracerebral haemorrhage
All grades	10 (36)	9 (43)	0.61
Severe grades (3/4)	3 (11)	1 (5)	0.63
Periventricular leucomalacia	3 (11)	1 (5)	0.63
Retinopathy
All grades	18 (64)	10 (48)	0.24
Severe grades (4/5)	4 (11)	0 (0)	0.13
Necrotising enterocolitis	2 (7)	0 (0)	0.50
Supplemental oxygen at discharge	6 (21)	1 (5)	0.21

Values are medians (range) or numbers (%)

ESTRA‐PRO, oestradiol and progesterone replacement.